Navigation Links
Cambrex Signs Agreement To Acquire ProSyntest AS

EAST RUTHERFORD, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Cambrex Karlskoga AB, a subsidiary of Cambrex Corporation (NYSE: CBM), is pleased to announce it has entered into a purchase agreement for all of the stock of ProSyntest AS, a privately held active pharmaceutical ingredients ("API") research and development company. ProSyntest employs approximately twenty five chemists located within the Tallinn Technology Park in Tallinn, Estonia. ProSyntest, formed in 1990 as a spin off from Tallinn University of Technology, has strengths in cost effective chemical route selection and sample generation, rapid scale up of products at kilo lab scale, as well as chiral and organometallic chemistries.

(Logo: )

"Cambrex Karlskoga has successfully worked with the ProSyntest chemists for the past fifteen years, and the acquisition of the business is a natural extension of our long standing relationship. ProSyntest, located in Eastern Europe, will enable Cambrex to more effectively compete in the high growth early clinical stage pharmaceutical custom development market and provide us with a strong pool of talented chemists to advance numerous proprietary strategic initiatives," commented Steven Klosk, Executive Vice President & COO of Cambrex Corporation.

The business will be renamed Cambrex Tallinn after completion of the acquisition. Cambrex intends to add more process and analytical chemists at the site and continue early API development work in Tallinn for scale up at Karlskoga and the other Cambrex manufacturing facilities.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
2. Pot bellies linked to early signs of cardiovascular disease
3. MSU engineering team designs innovative medical device
4. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
5. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
6. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
7. A new technology for cancer screening listens for the signs of cancer
8. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
9. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
10. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
11. KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc.
Post Your Comments:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: